CTIS2024-512436-29-00进行中（未招募）1 期
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA) - EPIC17
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 634
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patients with age 18 years or above; Patient is able to understand the nature of study and has provided written informed consent; Patients with Acute Coronary Syndrome and who underwent PCI during the admission with absorbable polymer stent who have been discharged on double antiplatelet therapy with Acetylsalicylic Acid and Ticagrelor or Prasugrel
排除标准
- •Patients with history of intracranial bleeding; Patients with contraindication for the use of Acetylsalicylic Acid or Clopidogrel or Ticagrelor or Prasugrel; Patients with major ischemic or hemorrhagic events during the first month; Patients with Thrombocytopenia <50,000 /µL; Patients with permanent oral anticoagulation; Patient is pregnant or breast feeding;Patients with impossibility to complete 1 year of follow-up; Patient´s life-expectancy is less than 24 months
研究者
相似试验
进行中（未招募）
4 期
VerifyNow to Optimise Platelet Inhibition in Coronary Acute SyndromePercutaneous Coronary InterventionAcute Coronary SyndromeAcute Myocardial InfarctionCoronary Artery DiseaseNCT04654052Fundación EPIC634
进行中（未招募）
不适用
Maintenance of platelet inhiBition with cangreloR after dIscontinuation ofthienopyriDines in patients undergoing surGEry: The BRIDGE trial - BRIDGESubjects who present with an acute coronary syndrome.MedDRA version: 12.0Level: LLTClassification code 10051592Term: Acute coronary syndromeMedDRA version: 12.0Level: PTClassification code 10051592Term: Acute coronary syndromeMedDRA version: 12.0Level: LLTClassification code 10006894Term: CABGEUCTR2008-001135-35-CZThe Medicines Company220
进行中（未招募）
不适用
Maintenance of platelet inhiBition with cangreloR after dIscontinuation ofthienopyriDines in patients undergoing surGEry: The BRIDGE trial - BRIDGEEUCTR2008-001135-35-GBThe Medicines Company220
进行中（未招募）
不适用
Maintenance of platelet inhiBition with cangreloR after dIscontinuation ofthienopyriDines in patients undergoing surGEry: The BRIDGE trial - BRIDGEEUCTR2008-001135-35-NLThe Medicines Company220
已完成
2 期
Maintenance of platelet inhiBition with cangreloR after dIscontinuation of thienopyriDines in patients undergoing surGEry: The BRIDGE trialplatelet inhibition10011082NL-OMON34815Medicines Company50